Allarity Therapeutics Inc
allarity.comWhat Do They Do?
Develops an experimental cancer drug and a tumor-based test to help select cancer patients for treatment.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with…View ↗
We are now singularly focused on the development of stenoparib and the parallel development of the stenoparib DRP® as a companion…View ↗
Our patented DRP® platform is a proprietary technology that enables the development of cancer drug-specific companion diagnostics that may…View ↗
How Do They Make Money?
External biotech clients pay for DRP analysis and gene-expression services; the company earns revenue when it delivers the assessed gene-expression signatures.
10-K for FY2025, filed Mar 30, 2026
$320K
-
10-K for FY2025, filed Mar 30, 2026
$320K ↗
Who Are Their Customers?
The company has service agreements with external biotech clients for DRP analysis and gene-expression services.
10-K for FY2025, filed Mar 30, 2026In 2024, we signed service agreements with external biotech clients for both DRP® analysis and gene expression services. Leveraging our…View ↗
Do Revenues Turn Into Profits?
No. It lost $11.2M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$12.6MView ↗
10-K for FY2025, filed Mar 30, 2026
−$11.2MView ↗
10-K for FY2025, filed Mar 30, 2026
−$14.8MView ↗
How Are They Changing?
A narrower drug pipeline
The older report described a pipeline that included dovitinib, stenoparib and IXEMPRA; the latest focuses on stenoparib and its companion diagnostic, and says other assets were terminated.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 30, 2026Our pipeline currently consists of three mid-stage clinical candidates for cancer and one anti-cancer asset in early-stage clinical…View ↗
We are now singularly focused on the development of stenoparib and the parallel development of the stenoparib DRP® as a companion…View ↗
Who Do They Compete With?
Competes with AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Merck KGaA, Regeneron Pharmaceuticals, Sanofi Genzyme, Roche, Foundation Medicine, Kura Oncology, Lantern Pharma, Novartis, GlaxoSmithKline, BeiGene, and Clovis Oncology
10-K for FY2025, filed Mar 30, 2026We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates…View ↗
Loading...
